Evidence map›Paper›PMID 40524237›Full record

ArticleJournal of cheminformatics2025

NanoBinder: a machine learning assisted nanobody binding prediction tool using Rosetta energy scores.

Palistha Shrestha, Chandana S Talwar, Jeevan Kandel, Kwang-Hyun Park, Kil To Chong, Eui-Jeon Woo, Hilal Tayara

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Palistha Shrestha *Department of Electronics and Information Engineering, Jeonbuk National University, Jeonju, 54896, Jeollabuk-do, Republic of Korea.
Chandana S Talwar *Disease Target Structure Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea.
Jeevan KandelGraduate School of Integrated Energy-AI, Jeonbuk National University, Jeonju, 54896, Jeollabuk-do, Republic of Korea.
Kwang-Hyun ParkDisease Target Structure Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea.
Kil To ChongDepartment of Electronics and Information Engineering, Jeonbuk National University, Jeonju, 54896, Jeollabuk-do, Republic of Korea. kitchong@jbnu.ac.kr.
Eui-Jeon WooDisease Target Structure Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea. ejwoo@kribb.re.kr.
Hilal TayaraSchool of International Engineering and Science, Jeonbuk National University, Jeonju, 54896, Jeollabuk-do, Republic of Korea. hilaltayara@jbnu.ac.kr.

Funding

Korea Institute of Energy Technology Evaluation and Planning 20204010600470KRIBB Research Initiative Program KGM1062511, KGM5382531, KGM1322511National Research Foundation of Korea NRF-2021M3A9G802559921, NRF-2022R1C1C100527013, NRF- 2021R1A2C201132814, NRF- 2020R1A2C2005612, NRF- 2022R1G1A1004613, RS-2021-NR059435 and 2021M3A9G802559922Research Program funded by National Research Council of Science & Technology (NST) [CRC22023-500] and [CRC22024-500]
6 · The paper itself

Abstract

Nanobodies offer significant therapeutic potential due to their small size, stability, and versatility. Although advancements in computational protein design have made designing de novo nanobodies increasingly feasible, there are limited tools specifically tailored for this purpose. Rosetta with its specialized protocols, is a prominent tool for nanobody design but is limited by a high false-negative rate, necessitating extensive high-throughput screening. This results in increased costs, time, and labor due to the need for large-scale experimentation and detailed structural analysis. To address current challenges in nanobody design, we introduce NanoBinder, an interpretable machine learning model that predicts nanobody-antigen binding using Rosetta energy scores. NanoBinder utilizes a Random Forest model trained on experimentally validated complexes and can be seamlessly integrated into the Rosetta software. It employs SHAP summary plots for interpretability, which helps identify key features influencing binding interactions. Experimentally validated on forty-nine diverse nanobodies, NanoBinder accurately predicts non-binders and shows reasonable performance in identifying binders. This approach significantly enhances predictive accuracy, reduces the need for extensive experimental assays, and accelerates nanobody development, thereby offering a powerful tool to mitigate the costs, time, and labor associated with high-throughput screening.Scientific contribution This study introduces NanoBinder, a machine learning framework for predicting nanobody-antigen binding using Rosetta-derived energy features. Through rigorous experimental validation across diverse nanobody sets, NanoBinder enhances nanobody screening workflows by reducing false positives and minimizing reliance on extensive wet-lab assays. The approach bridges the gap between physics-based modeling and data-driven prediction in nanobody design.

Identifiers

PMID40524237
PMCPMC12172308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.